GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (LTS:0IIM) » Definitions » Cyclically Adjusted PB Ratio

Esperion Therapeutics (LTS:0IIM) Cyclically Adjusted PB Ratio : 0.32 (As of Jun. 03, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Esperion Therapeutics Cyclically Adjusted PB Ratio?

As of today (2025-06-03), Esperion Therapeutics's current share price is $0.9407. Esperion Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $2.92. Esperion Therapeutics's Cyclically Adjusted PB Ratio for today is 0.32.

The historical rank and industry rank for Esperion Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

LTS:0IIM' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.18   Med: 1.44   Max: 9.78
Current: 0.3

During the past years, Esperion Therapeutics's highest Cyclically Adjusted PB Ratio was 9.78. The lowest was 0.18. And the median was 1.44.

LTS:0IIM's Cyclically Adjusted PB Ratio is ranked better than
91.49% of 693 companies
in the Drug Manufacturers industry
Industry Median: 1.94 vs LTS:0IIM: 0.30

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Esperion Therapeutics's adjusted book value per share data for the three months ended in Mar. 2025 was $-2.167. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.92 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Esperion Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Esperion Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics Cyclically Adjusted PB Ratio Chart

Esperion Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.78 1.02 1.38 0.74 0.66

Esperion Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.59 0.46 0.66 0.50

Competitive Comparison of Esperion Therapeutics's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Esperion Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Esperion Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Esperion Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Esperion Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.9407/2.92
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Esperion Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Esperion Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-2.167/134.9266*134.9266
=-2.167

Current CPI (Mar. 2025) = 134.9266.

Esperion Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 13.586 100.684 18.207
201509 13.168 100.392 17.698
201512 12.757 99.792 17.248
201603 12.323 100.470 16.549
201606 11.886 101.688 15.771
201609 11.270 101.861 14.928
201612 10.135 101.863 13.425
201703 8.518 102.862 11.173
201706 6.821 103.349 8.905
201709 10.619 104.136 13.759
201712 9.302 104.011 12.067
201803 8.005 105.290 10.258
201806 6.564 106.317 8.330
201809 4.915 106.507 6.227
201812 2.949 105.998 3.754
201903 6.504 107.251 8.182
201906 4.784 108.070 5.973
201909 2.521 108.329 3.140
201912 0.726 108.420 0.903
202003 -1.824 108.902 -2.260
202006 3.080 108.767 3.821
202009 0.322 109.815 0.396
202012 -3.709 109.897 -4.554
202103 -10.289 111.754 -12.422
202106 -11.582 114.631 -13.633
202109 -13.534 115.734 -15.778
202112 -3.235 117.630 -3.711
202203 -4.076 121.301 -4.534
202206 -4.516 125.017 -4.874
202209 -4.099 125.227 -4.417
202212 -4.342 125.222 -4.679
202303 -3.779 127.348 -4.004
202306 -3.688 128.729 -3.866
202309 -3.656 129.860 -3.799
202312 -3.849 129.419 -4.013
202403 -1.567 131.776 -1.604
202406 -1.769 132.554 -1.801
202409 -1.894 133.029 -1.921
202412 -1.985 133.157 -2.011
202503 -2.167 134.927 -2.167

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Esperion Therapeutics  (LTS:0IIM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Esperion Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Esperion Therapeutics Business Description

Traded in Other Exchanges
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Esperion Therapeutics Headlines

No Headlines